The timing of drug administration during the clinical course of COVID-19 is important, especially so, for a general immune system dampening treatment like dexamethasone, which interestingly may also diminish leukotriene production by virtue of its effects to block substrate supply via the enzyme cytosolic phospholipase A2 (Yao et al., 1999). Here, PLA2G4A is linked to COVID-19.